Millions with ME/CFS

Martin aka paused||M.E.

Senior Member
I have started a new Podcast.

This Podcast will discuss research, living with ME/CFS and hopefully bring together researchers and patients.

I’m this first episode I talked to Fereshteh. Fereshteh Jahaniani is a Chief Science Officer at Stanford University and Leader of ME/CFS related disorders Multi-Omics study at Stanford. In this episode we talk about personalised medicine in ME/CFS, platelets, infections, Flouroquinolones and why ME/CFS isn’t solved yet.

I hope you’ll enjoy it.



Senior Member
Thank you very much Martin for the podcast. I could only listen for 30 Min, but I will continue tomorrow.
Here is something you may like to read:

"genetic lipid disorders lipids in the muscles"

This is the most important:
Metabolic lipid muscle disorders: biomarkers and treatment

the best part in this paper:

An extensive review of literature describing patients with PCD, MADD, and CPT-II reveals that these defects are rare but treatable. Although, even when treated, patients with CPT-II and MADD might present episodes of transient weakness and myalgia. The treatment of NLSDs is still elusive and will need further translational research.

other publication:
Intramuscular lipids refer to lipids contained in both intramuscular adipose tissue and muscle fibres. The intramuscular adipose tissue is comprised of cells located along the fibres and in the interfascicular area (Cassens & Cooper, 1971). The fat cells are isolated or in clusters.

What is lipid myopathy?
Neutral lipid storage disease with myopathy is a condition in which fats (lipids) are stored abnormally in organs and tissues throughout the body. People with this condition have muscle weakness (myopathy) due to the accumulation of fats in muscle tissue.

What are lipid storage disorders?
Lipid storage diseases, or the lipidoses, are a group of inherited metabolic disorders in which harmful amounts of fatty materials (lipids) accumulate in various cells and tissues in the body.
Last edited: